Last reviewed · How we verify

NCT03109574: ADOPT

Access in Dialysis for Better Outcomes in Patient Therapy

Completed NA Last updated 5 November 2019
What this trial tests

NA trial testing BioFlo DuraMax Chronic Hemodialysis Catheter in Central Venous Catheter in 92 participants. Completed in 30 June 2019.

Timeline
29 August 2016
Primary endpoint
30 June 2019
30 June 2019

Quick facts

Lead sponsorWilliam Osler Health System
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposehealth services research
Enrollment92
Start date29 August 2016
Primary completion30 June 2019
Estimated completion30 June 2019
Sites3 locations across Canada

Drugs / interventions tested

Conditions studied

Sponsor

William Osler Health System

Who can join

18 and older, any sex, with Central Venous Catheter or Catheter-Related Bloodstream Infection (CRBSI) Nos. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, multi-center health economic study in Canada. Participants will be randomly assigned to receive either the study or control dialysis catheter. The primary objective is to evaluate resource utilization in Ontario related to hemodialysis catheter placement including tissue plasminogen activator (tPA) usage, catheter exchange rates, catheter patency, and missed dialysis days.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Central Venous Catheter

Currently open trials in the same condition.

Other William Osler Health System trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03109574.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing